K
K36 Therapeutics
Clinical stage biopharmaceutical company developing targeted therapies for patients with cancer
About K36 Therapeutics
K36 Therapeutics, a clinical-stage biopharmaceutical company established in February 2021, focuses on developing targeted therapies for cancers with significant unmet medical needs. The company was founded with the mission to translate the epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics. The President and CEO, Terry Connolly, Ph.D., brings over two decades of biopharmaceutical industry experience to the company, with a background that includes roles in research, development, business development, and executive leadership at companies like Celgene, Roche, and Wyeth. His journey through process chemistry, alliance management, and corporate transactions, including dozens of licensing deals and acquisitions, provides a robust foundation for leading K36.
K36 Therapeutics' business centers on the clinical development of its lead drug candidate, KTX-1001. This orally administered small molecule was exclusively licensed from Novartis and is designed as a selective inhibitor of the histone methyltransferase MMSET (also known as NSD2). The company operates in the precision oncology market, specifically targeting cancers driven by epigenetic dysregulation. The primary client base consists of cancer patients, particularly those with multiple myeloma. K36's business model is typical of a clinical-stage biotech, focusing on advancing its lead asset through clinical trials to eventually secure regulatory approval and commercialization, a process funded by venture capital.
The company has demonstrated considerable fundraising ability, securing a $30 million Series A in December 2021 and a subsequent $70 million Series B in June 2023. The financing rounds were supported by a syndicate of investors including Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest, and Bristol-Myers Squibb. These funds are allocated to advance KTX-1001 through its ongoing Phase 1 clinical trials, both as a monotherapy and in combination with existing standard-of-care agents. KTX-1001 is being developed for patients with relapsed and refractory multiple myeloma, with a specific focus on a high-risk subgroup characterized by the t(4;14) genetic translocation, which is present in up to 20% of multiple myeloma patients and is associated with a poor prognosis. The therapy works by inhibiting MMSET, an enzyme that is overexpressed in these patients, thereby aiming to reverse the oncogenic programs that drive tumor growth and resistance to other therapies. In November 2023, the company received the "Overall BioPharma Startup of the Year" award from BioTech Breakthrough, recognizing its work on KTX-1001.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 29.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2023 | $70M | $280M | Eight Roads Ventures · Bristol-Myers Squibb · Atlas Venture · F-Prime | ↗ |
| SERIES AOther financing | Dec 2021 | $30M | $120M | F-Prime · Eight Roads Ventures · Atlas Venture | ↗ |
Growth signals
Latest recorded traffic for K36 Therapeutics is 3.3K monthly website visits, up 83.3% over the last three months. K36 Therapeutics's team declined 27.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
K36 Therapeutics in the Cambridge ecosystem
The K36 Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Atlas Venture
Eight Roads Ventures
F-Prime
Nextech Invest
Bristol-Myers Squibb
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about K36 Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See K36 Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









